Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
Amy S PallerElaine C SiegfriedEric L SimpsonMichael J CorkRobert SidburyIris H ChenFaisal A KhokharJing XiaoAriane Dubost-BramaAshish BansalPublished in: American journal of clinical dermatology (2024)
ClinicalTrials.gov Identifiers: NCT02612454 and NCT03346434 (part B).